These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 33420915)

  • 41. [
    Green MA; Hutchins GD; Bahler CD; Tann M; Mathias CJ; Territo W; Sims J; Polson H; Alexoff D; Eckelman WC; Kung HF; Fletcher JW
    Mol Imaging Biol; 2020 Jun; 22(3):752-763. PubMed ID: 31429050
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Preclinical evaluation of 86Y-labeled inhibitors of prostate-specific membrane antigen for dosimetry estimates.
    Banerjee SR; Foss CA; Pullambhatla M; Wang Y; Srinivasan S; Hobbs RF; Baidoo KE; Brechbiel MW; Nimmagadda S; Mease RC; Sgouros G; Pomper MG
    J Nucl Med; 2015 Apr; 56(4):628-34. PubMed ID: 25722448
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Novel multifunctional
    Kwon YD; Lee JY; La MT; Lee SJ; Lee SH; Park JH; Kim HK
    Eur J Med Chem; 2020 Mar; 189():112099. PubMed ID: 32014792
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Development of
    Potemkin R; Strauch B; Kuwert T; Prante O; Maschauer S
    Mol Pharm; 2020 Mar; 17(3):933-943. PubMed ID: 32011889
    [TBL] [Abstract][Full Text] [Related]  

  • 45. AAZTA: An Ideal Chelating Agent for the Development of
    Nagy G; Szikra D; Trencsényi G; Fekete A; Garai I; Giani AM; Negri R; Masciocchi N; Maiocchi A; Uggeri F; Tóth I; Aime S; Giovenzana GB; Baranyai Z
    Angew Chem Int Ed Engl; 2017 Feb; 56(8):2118-2122. PubMed ID: 28097756
    [TBL] [Abstract][Full Text] [Related]  

  • 46. PET imaging of prostate cancer xenografts with a highly specific antibody against the prostate-specific membrane antigen.
    Elsässer-Beile U; Reischl G; Wiehr S; Bühler P; Wolf P; Alt K; Shively J; Judenhofer MS; Machulla HJ; Pichler BJ
    J Nucl Med; 2009 Apr; 50(4):606-11. PubMed ID: 19289418
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Design and Preclinical Evaluation of an Albumin-Binding PSMA Ligand for
    Umbricht CA; Benešová M; Hasler R; Schibli R; van der Meulen NP; Müller C
    Mol Pharm; 2018 Dec; 15(12):5556-5564. PubMed ID: 30376344
    [TBL] [Abstract][Full Text] [Related]  

  • 48. (R)-NODAGA-PSMA: A Versatile Precursor for Radiometal Labeling and Nuclear Imaging of PSMA-Positive Tumors.
    Gourni E; Canovas C; Goncalves V; Denat F; Meyer PT; Maecke HR
    PLoS One; 2015; 10(12):e0145755. PubMed ID: 26700033
    [TBL] [Abstract][Full Text] [Related]  

  • 49. One-step
    Zhao X; Lv G; Li K; Peng Y; Liu Q; Qiu L; Lin J
    Nucl Med Biol; 2020; 82-83():72-79. PubMed ID: 32109829
    [TBL] [Abstract][Full Text] [Related]  

  • 50. One-Step
    Kuo HT; Lepage ML; Lin KS; Pan J; Zhang Z; Liu Z; Pryyma A; Zhang C; Merkens H; Roxin A; Perrin DM; Bénard F
    J Nucl Med; 2019 Aug; 60(8):1160-1166. PubMed ID: 30737299
    [TBL] [Abstract][Full Text] [Related]  

  • 51. 68Ga- and 177Lu-Labeled PSMA I&T: Optimization of a PSMA-Targeted Theranostic Concept and First Proof-of-Concept Human Studies.
    Weineisen M; Schottelius M; Simecek J; Baum RP; Yildiz A; Beykan S; Kulkarni HR; Lassmann M; Klette I; Eiber M; Schwaiger M; Wester HJ
    J Nucl Med; 2015 Aug; 56(8):1169-76. PubMed ID: 26089548
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Design, synthesis, radiolabeling and biological evaluation of new urea-based peptides targeting prostate specific membrane antigen.
    Mosayebnia M; Hajimahdi Z; Beiki D; Rezaeianpour M; Hajiramezanali M; Geramifar P; Sabzevari O; Amini M; Hatamabadi D; Shahhosseini S
    Bioorg Chem; 2020 Jun; 99():103743. PubMed ID: 32217372
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Synthesis,
    Hasnowo LA; Larkina MS; Plotnikov E; Bodenko V; Yuldasheva F; Stasyuk E; Petrov SA; Zyk NY; Machulkin AE; Vorozhtsov NI; Beloglazkina EK; Nenajdenko VG; Tolmachev V; Orlova A; Majouga AG; Yusubov MS
    Int J Mol Sci; 2023 Jul; 24(15):. PubMed ID: 37569582
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Optimization of reaction conditions for the radiolabeling of DOTA and DOTA-peptide with (44m/44)Sc and experimental evidence of the feasibility of an in vivo PET generator.
    Huclier-Markai S; Kerdjoudj R; Alliot C; Bonraisin AC; Michel N; Haddad F; Barbet J
    Nucl Med Biol; 2014 May; 41 Suppl():e36-43. PubMed ID: 24361353
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Synthesis of novel DOTA-/AAZTA-based bifunctional chelators: Solution thermodynamics, peptidomimetic conjugation, and radiopharmaceutical evaluation.
    Liu X; Chen L; Li Y; He C; Zhang X; Zhou H; Bao G; Zhu X; Xiang G; Ma X
    Biomed Pharmacother; 2023 Sep; 165():115114. PubMed ID: 37467649
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Copper-mediated radioiodination and radiobromination via aryl boronic precursor and its application to
    Kondo Y; Kimura H; Sasaki I; Watanabe S; Ohshima Y; Yagi Y; Hattori Y; Koda M; Kawashima H; Yasui H; Ishioka NS
    Bioorg Med Chem; 2022 Sep; 69():116915. PubMed ID: 35802951
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Accelerator-Based Production of Scandium Radioisotopes for Applications in Prostate Cancer: Toward Building a Pipeline for Rapid Development of Novel Theranostics.
    Meier JP; Zhang HJ; Freifelder R; Bhuiyan M; Selman P; Mendez M; Kankanamalage PHA; Brossard T; Pusateri A; Tsai HM; Leoni L; Penano S; Ghosh K; Broder BA; Markiewicz E; Renne A; Stadler W; Weichselbaum R; Nolen J; Kao CM; Chitneni SK; Rotsch DA; Szmulewitz RZ; Chen CT
    Molecules; 2023 Aug; 28(16):. PubMed ID: 37630292
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Preclinical Evaluation of a High-Affinity Sarcophagine-Containing PSMA Ligand for
    Kelly JM; Ponnala S; Amor-Coarasa A; Zia NA; Nikolopoulou A; Williams C; Schlyer DJ; DiMagno SG; Donnelly PS; Babich JW
    Mol Pharm; 2020 Jun; 17(6):1954-1962. PubMed ID: 32286841
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Synthesis and radiopharmacological evaluation of a high-affinity and metabolically stabilized 18F-labeled bombesin analogue for molecular imaging of gastrin-releasing peptide receptor-expressing prostate cancer.
    Richter S; Wuest M; Krieger SS; Rogers BE; Friebe M; Bergmann R; Wuest F
    Nucl Med Biol; 2013 Nov; 40(8):1025-34. PubMed ID: 23969085
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Targeting PSMA with a Cu-64 Labeled Phosphoramidate Inhibitor for PET/CT Imaging of Variant PSMA-Expressing Xenografts in Mouse Models of Prostate Cancer.
    Nedrow JR; Latoche JD; Day KE; Modi J; Ganguly T; Zeng D; Kurland BF; Berkman CE; Anderson CJ
    Mol Imaging Biol; 2016 Jun; 18(3):402-10. PubMed ID: 26552656
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.